HTH

SensArs is a medical equipment manufacturing company specializing in neuromodulation for diabetic neuropathy. The company's flagship product, SENSY, is a healthcare technology system designed to restore natural sensations in the feet of patients suffering from amputation or nerve damage. SensArs has developed a patented implantable neurostimulator electrode that delivers targeted electrical impulses to the nerve fibers responsible for transmitting pain signals. This innovative approach enables healthcare professionals to enhance patient functionality and provides a long-term solution for pain management. Through its advancements in neurostimulation technology, SensArs aims to improve the quality of life for individuals affected by sensory loss.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is notable for its lead drug, Glunozumab, a monoclonal antibody that employs a novel mechanism of action. This drug hyperactivates both vascular and neuronal NMDA receptors, leading to off-target toxicity that can disrupt the blood-brain and blood-spinal cord barriers, resulting in neuronal excitotoxicity associated with conditions such as stroke and multiple sclerosis. Lys Therapeutics aims to address neuroinflammation and its effects on neurodegeneration through innovative biotherapies.

Leuko Labs, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in the development of healthcare equipment. The company's primary product, PointCheck, is a non-invasive device designed to monitor and count white blood cells. This innovative technology allows for more frequent testing of immunosuppressed patients, such as those undergoing chemotherapy, enhancing their quality of life and clinical outcomes. The device is particularly beneficial as it eliminates the need for invasive blood draws and laboratory infrastructure, making it more accessible and convenient for patients.

Neurofenix is a company focused on enhancing rehabilitation for stroke victims through innovative technology. It has developed an upper limb rehabilitation device that aims to make therapy more autonomous, enjoyable, and accessible. This device features a hand-training controller that allows users to engage their impaired hand in interactive video games, transforming traditional rehabilitation exercises into fun and immersive experiences. By providing patients with effective arm and hand therapy both in clinical settings and from the comfort of their homes, Neurofenix seeks to empower stroke survivors in their recovery journeys.

Endostart is a developer of innovative colonoscopy technologies aimed at improving the efficiency and safety of colonoscopy procedures. The company has created a proprietary Magnetic Balloon Anchoring Technology, which includes a magnetic balloon guide, a ferrofluid syringe, and a multi-use magnetic handpiece. These advancements are designed to assist healthcare professionals in guiding and navigating colonoscopy procedures, thereby reducing wall stress and minimizing the need for general anesthesia. Through its unique approach, Endostart seeks to enhance patient comfort and streamline the colonoscopy process.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

AirGo specializes in developing non-invasive medical respiratory sensors that enable real-time monitoring of minute ventilation and breath dynamics. The company’s innovative device consists of a wearable, miniaturized recorder unit and a medical-grade holter, which is worn over the patient's floating ribs. This technology allows for continuous monitoring during various activities, including daily routines, sleep, and exercise. By measuring live circumference changes, AirGo provides automated clinical data that enhances patient care. The proprietary algorithms integrated into the system generate real-time alerts and comprehensive diagnostic reports, facilitating faster and more precise diagnoses for physicians. AirGo’s platform is designed for long-term remote monitoring and is being prepared for large-scale deployment with compliance to data protection regulations.